Search

Search Constraints

You searched for: Author/Creator Ma, Keying

Search Results

1. 251 Type II but not type I interferon signifies clinical response to ustekinumab in patients with systemic lupus erythematosus. (April 2019)

4. Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials. Issue 2 (19th May 2021)

7. Suppression of Serum Interferon‐γ Levels as a Potential Measure of Response to Ustekinumab Treatment in Patients With Systemic Lupus Erythematosus. Issue 3 (1st February 2021)

9. Validated and longitudinally stable asthma phenotypes based on cluster analysis of the ADEPT study. Issue 1 (December 2016)